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The concept of global vascular risk is recognized as an important predictor
of major events in patients with coronary artery disease.
We aimed to evaluate long term clinical outcome among patients with
peripheral vascular disease (PVD) following coronary artery bypass grafting.
We studied 589 consecutive patients who underwent isolated coronary
artery bypass grafting between January 2003 and June 2005. The impact of
peripheral artery disease was assessed by comparing a two year follow-up of
2 groups of patients: patients with (n=243) and without (n=346) PVD.
Patients with PVD were significantly older (70±9 vs 64±11 years p<0.001)
and were more often men (80.3% vs 74.2% p=0.04) than those without PVD.
They had a higher incidence of hypertension (p=0.002), chronic renal dysfunc-
tion (p<0.01), chronic pulmonary disease (p=0.005) with higher EuroSCORE
cardiac risk (9.6±6 vs 3.8±3 p<0.01). No significant difference was noted
between the 2 groups with regard to left ventricular ejection fraction.
The analysis of ischemic events showed that peripheral ischemic events
(19.7% vs 4.6% p<0.001) and more specifically cerebrovascular events (9% vs
3.5% p<0.01) were significantly higher in PVD group. Neither myocardial inf-
arction (6.2% vs 6.7% p=ns) nor new coronary revascularization (9.8% vs
14.5% p=ns) differed significantly among the 2 groups;
The two-year follow up showed a rate of survival markedly lower for patents
with PVD than those with isolated coronary disease. Two-year cumulative sur-
vival rates were 76.6% for patients with PVD and 94.1% for those with iso-
lated coronary disease (p<0.001).
Differences in outcome remained significant after adjusting all variables
including medical treatment, PVD appeared as an independent predictive
factor of all cause mortality with a hazard ration of 3.2 [95%CI (1.8-5.7)
p<0.001].
PVD was not only highly prevalent but also strongly associated with long
term mortality after coronary artery bypass surgery.
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Background: In the western countries, a high prevalence of lower-extrem-
ities peripheral artery disease (LE-PAD) is reported in the elderly. The epide-
miological transition in the developing countries might also involve this
affection, but data regarding LE-PAD in Sub-Saharan Africa are unknown. We
sought to determine the prevalence and risk factors for LE-PAD in the general
elder population in 2 Sub-Saharan African countries: Congo and Central
African Republic.
Methods: We performed 2 cross-sectional studies in the populations aged
>65 years in two representative districts of Brazzaville, Congo and Bangui,
Central African Republic. Demographic data, as well as medical history, were
collected along with clinical and biological data to determine the traditional
cardiovascular disease risk factors. The ankle-brachial index (ABI) was used
to define LE-PAD, when ABI <0.90. An ABI >1.40 was considered to define
medial calcinosis (MC).
Results: Among the 997 participants (age 73.6+6.5 yrs, 40.7% males), 239
(24.0%) had LE-PAD, while 69 (6.9%) had MC. Adjusted for age, gender and
study site, factors significantly associated with LE-PAD were hypertension
(OR=1.75, 95%CI: 1.24-2.48, p=0.002) and daily alcohol consumption
(OR=0.72, 95%CI: 0.53-0.98, p=0.04). A borderline association was found with
a body-mass index >30kg/m2 (OR=1.56, 95%CI: 0.95-2.58, p=0.08). Of note,
neither smoking nor diabetes were found as significant associated risk factors.
Adjusted for age, gender and study site, factors significantly associated with
MC were schooling (vs. no school education, OR=3.20, 95%CI: 1.69-6.04,
p=0.0003) and hypertension (OR=0.38, 95%CI: 0.22-0.66, p=0.0006), while
alcohol consumption (OR=0.63, 95%CI: 0.37-1.07, p=0.09) and heart rate
(OR=1.23, 95%CI: 0.98-1.56, p=0.07) presented a borderline association.
Conclusions: In this first population study in Central Africa, we found a
very high prevalence of LE-PAD in the elderly, and highlight particularities
regarding the associated risk factors, different from data published in western
countries.
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Background: In the EUROPA study, perindopril 8 mg/day significantly
reduced the combined primary end point (PEP) of cardiovascular death, non-
fatal myocardial infarction (MI), and/or resuscitated cardiac arrest by 20%,
compared with placebo, after 4.2 years in 12 218 patients with stable coronary
artery disease (CAD) without heart failure. The aim of this new analysis is to
calculate the benefits of perindopril 8 mg/day in CAD patients with hyperten-
sion according to JNC-7 cutoff.
Methods: In EUROPA, 7064 (57.8%) patients were hypertensive with
SBP/DBP ≥ 140/90 mm Hg or current antihypertensive therapy. The baseline
characteristics of these patients were not different from the whole EUROPA
population: 63% had a previous MI (n=4469) and 54% were previously revas-
cularized (n=3839).
Results: In EUROPA patients with hypertension, the incidence of the PEP
with perindopril (n=3506) and placebo (n=3558) was 9% and 11.1%, respec-
tively. The relative risk reduction (RRR) of PEP with perindopril was 18.6%
(95% CI [6.9; 30.8]; P=0.004).
Among EUROPA patients with hypertension, the RRR of fatal and nonfatal
MI was 26.4% (95% CI [11.6; 38.8]; P=0.001), with a rate of 5.6% and 7.6%
with perindopril and placebo, respectively. This reduction in risk for MI was
consistent whether the patients had had previous MI (RRR, 32.6% [95% CI
(16; 45.9); P<0.001]) or revascularization (RRR, 30.2%, [95% CI (7.7; 47.2);
P=0.011]).
Finally, heart failure was significantly reduced with perindopril (1.2%)
versus placebo (2%) by 40.2% (95% CI [12.4; 59.2]; P=0.008). In these CAD
patients with hypertension, discontinuation for hypotension was particularly
low with perindopril (0.6%), similar to placebo (0.2%), confirming the safety
of high-dose perindopril (8 mg/day) in terms of BP lowering.
Conclusions: In the EUROPA study, the benefit with perindopril 8 mg/day
was consistent among hypertensive CAD patients, even in case of previous MI
and/or revascularization. These results are in line with the 2006 ESC guide-
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